MedicarePartD.guide

A non-government resource built from CMS public data

IL-17, IL-23 and IL-12/23 biologics on HealthSpring Assurance Rx (S5617-008)

Stelara and its biosimilars, Skyrizi, Tremfya, Cosentyx and Taltz, for psoriasis, psoriatic arthritis and Crohn's, checked against this plan's 2026 formulary (its list of covered drugs).

Plan type
Stand-alone drug plan (PDP), Connecticut + 3 more
Premium
$139.30/month
Deductible
$615.00
Change plan

6 of 9 IL-17 and IL-23 biologics are covered on this plan. All 6 require prior authorization.

3 aren't on the formulary, including Wezlana and Taltz.

  • Stelara
    ustekinumab
    Covered · prior auth
    from $1,212.25
    Tier 5
  • ustekinumab biosimilars
    Wezlana, Selarsdi, Pyzchiva and others
    Covered · prior auth
    from $1,212.25
    Tier 5
  • Selarsdi
    ustekinumab-aekn
    Covered · prior auth
    from $451.26
    Tier 3
  • Skyrizi
    risankizumab
    Covered · prior auth
    from $2,204.83
    Tier 5
  • Tremfya
    guselkumab
    Covered · prior auth
    from $3,643.29
    Tier 5
  • Cosentyx
    secukinumab
    Covered · prior auth
    from $5,835.12
    Tier 5
Not on the formulary
Wezlana, Taltz, Bimzelx

Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.

Full plan details · This plan's whole drug list